Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: The Japanese experience

Tsuguo Naruke, Ryosuke Tsuchiya, Haruhiko Kondo, Hisao Asamura

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Background. A new TNM staging system was proposed, and the previous system was revised in 1997. Methods. To evaluate the new TNM staging system for lung cancer, records of 3,043 lung cancer patients who underwent pulmonary resection at the National Cancer Center Hospital, Tokyo, were analyzed. Results. With regard to clinical stages, 3 patients had occult carcinoma; 786 patients had stage IA disease; 759 patients, stage IB; 54 patients, stage IIA; 469 patients, stage IIB; 582 patients, stage IIIA; 211 patients, stage IIIB; and 179 patients, stage IV. The 5-year survival rates for the respective stages were 70.8% for stage IA, 44.0% for stage IB, 41.1% for stage IIA, 36.9% for stage IIB, 22.7% for stage IIIA, 20.1% for stage IIIB, and 21.6% for stage IV. In terms of postoperative stages, 7 patients were classified in stage 0, 610 in stage IA, 506 in stage IB, 114 in stage IIA, 432 in stage IIB, 702 in stage IIIA, 448 in stage IIIB, and 224 in stage IV. The 5-year survival rates were as follows: stage IA, 79.0%; stage IB, 59.7%; stage IIA, 56.9%; stage IIB, 45.0%; stage IIIA, 23.6%; stage IIIB, 16.5%; and stage IV, 5.1%. Conclusions. In the clinical stage, there were significant prognostic differences between stage IA and stage IB, stage IIB and IIIA, and stage IIIA and stage IIIB, but there was no significant difference in 5-year survival rates between stage IB and stage IIA, stage IIA, and IIB, and stage IIIB and stage IV. In the postoperative stage, there were significant differences in 5-year survival rates between each stage except for stage IB and stage IIA.

Original languageEnglish
Pages (from-to)1759-1764
Number of pages6
JournalAnnals of Thoracic Surgery
Volume71
Issue number6
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Bronchogenic Carcinoma
Neoplasm Staging
Survival
Survival Rate
Lung Neoplasms
Cancer Care Facilities
Tokyo
Carcinoma
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification : The Japanese experience. / Naruke, Tsuguo; Tsuchiya, Ryosuke; Kondo, Haruhiko; Asamura, Hisao.

In: Annals of Thoracic Surgery, Vol. 71, No. 6, 2001, p. 1759-1764.

Research output: Contribution to journalArticle

@article{278e7b01041c4cbebb803b37c66ddc8a,
title = "Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: The Japanese experience",
abstract = "Background. A new TNM staging system was proposed, and the previous system was revised in 1997. Methods. To evaluate the new TNM staging system for lung cancer, records of 3,043 lung cancer patients who underwent pulmonary resection at the National Cancer Center Hospital, Tokyo, were analyzed. Results. With regard to clinical stages, 3 patients had occult carcinoma; 786 patients had stage IA disease; 759 patients, stage IB; 54 patients, stage IIA; 469 patients, stage IIB; 582 patients, stage IIIA; 211 patients, stage IIIB; and 179 patients, stage IV. The 5-year survival rates for the respective stages were 70.8{\%} for stage IA, 44.0{\%} for stage IB, 41.1{\%} for stage IIA, 36.9{\%} for stage IIB, 22.7{\%} for stage IIIA, 20.1{\%} for stage IIIB, and 21.6{\%} for stage IV. In terms of postoperative stages, 7 patients were classified in stage 0, 610 in stage IA, 506 in stage IB, 114 in stage IIA, 432 in stage IIB, 702 in stage IIIA, 448 in stage IIIB, and 224 in stage IV. The 5-year survival rates were as follows: stage IA, 79.0{\%}; stage IB, 59.7{\%}; stage IIA, 56.9{\%}; stage IIB, 45.0{\%}; stage IIIA, 23.6{\%}; stage IIIB, 16.5{\%}; and stage IV, 5.1{\%}. Conclusions. In the clinical stage, there were significant prognostic differences between stage IA and stage IB, stage IIB and IIIA, and stage IIIA and stage IIIB, but there was no significant difference in 5-year survival rates between stage IB and stage IIA, stage IIA, and IIB, and stage IIIB and stage IV. In the postoperative stage, there were significant differences in 5-year survival rates between each stage except for stage IB and stage IIA.",
author = "Tsuguo Naruke and Ryosuke Tsuchiya and Haruhiko Kondo and Hisao Asamura",
year = "2001",
doi = "10.1016/S0003-4975(00)02609-6",
language = "English",
volume = "71",
pages = "1759--1764",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification

T2 - The Japanese experience

AU - Naruke, Tsuguo

AU - Tsuchiya, Ryosuke

AU - Kondo, Haruhiko

AU - Asamura, Hisao

PY - 2001

Y1 - 2001

N2 - Background. A new TNM staging system was proposed, and the previous system was revised in 1997. Methods. To evaluate the new TNM staging system for lung cancer, records of 3,043 lung cancer patients who underwent pulmonary resection at the National Cancer Center Hospital, Tokyo, were analyzed. Results. With regard to clinical stages, 3 patients had occult carcinoma; 786 patients had stage IA disease; 759 patients, stage IB; 54 patients, stage IIA; 469 patients, stage IIB; 582 patients, stage IIIA; 211 patients, stage IIIB; and 179 patients, stage IV. The 5-year survival rates for the respective stages were 70.8% for stage IA, 44.0% for stage IB, 41.1% for stage IIA, 36.9% for stage IIB, 22.7% for stage IIIA, 20.1% for stage IIIB, and 21.6% for stage IV. In terms of postoperative stages, 7 patients were classified in stage 0, 610 in stage IA, 506 in stage IB, 114 in stage IIA, 432 in stage IIB, 702 in stage IIIA, 448 in stage IIIB, and 224 in stage IV. The 5-year survival rates were as follows: stage IA, 79.0%; stage IB, 59.7%; stage IIA, 56.9%; stage IIB, 45.0%; stage IIIA, 23.6%; stage IIIB, 16.5%; and stage IV, 5.1%. Conclusions. In the clinical stage, there were significant prognostic differences between stage IA and stage IB, stage IIB and IIIA, and stage IIIA and stage IIIB, but there was no significant difference in 5-year survival rates between stage IB and stage IIA, stage IIA, and IIB, and stage IIIB and stage IV. In the postoperative stage, there were significant differences in 5-year survival rates between each stage except for stage IB and stage IIA.

AB - Background. A new TNM staging system was proposed, and the previous system was revised in 1997. Methods. To evaluate the new TNM staging system for lung cancer, records of 3,043 lung cancer patients who underwent pulmonary resection at the National Cancer Center Hospital, Tokyo, were analyzed. Results. With regard to clinical stages, 3 patients had occult carcinoma; 786 patients had stage IA disease; 759 patients, stage IB; 54 patients, stage IIA; 469 patients, stage IIB; 582 patients, stage IIIA; 211 patients, stage IIIB; and 179 patients, stage IV. The 5-year survival rates for the respective stages were 70.8% for stage IA, 44.0% for stage IB, 41.1% for stage IIA, 36.9% for stage IIB, 22.7% for stage IIIA, 20.1% for stage IIIB, and 21.6% for stage IV. In terms of postoperative stages, 7 patients were classified in stage 0, 610 in stage IA, 506 in stage IB, 114 in stage IIA, 432 in stage IIB, 702 in stage IIIA, 448 in stage IIIB, and 224 in stage IV. The 5-year survival rates were as follows: stage IA, 79.0%; stage IB, 59.7%; stage IIA, 56.9%; stage IIB, 45.0%; stage IIIA, 23.6%; stage IIIB, 16.5%; and stage IV, 5.1%. Conclusions. In the clinical stage, there were significant prognostic differences between stage IA and stage IB, stage IIB and IIIA, and stage IIIA and stage IIIB, but there was no significant difference in 5-year survival rates between stage IB and stage IIA, stage IIA, and IIB, and stage IIIB and stage IV. In the postoperative stage, there were significant differences in 5-year survival rates between each stage except for stage IB and stage IIA.

UR - http://www.scopus.com/inward/record.url?scp=0034989470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034989470&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(00)02609-6

DO - 10.1016/S0003-4975(00)02609-6

M3 - Article

C2 - 11426744

AN - SCOPUS:0034989470

VL - 71

SP - 1759

EP - 1764

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -